Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog

The Therapeutic Goods Administration (TGA) in Australia has released a safety warning concerning GLP-1 receptor agonists, including Ozempic. The alert highlights potential links to suicidal thoughts and the reduced effectiveness of oral contraceptives.

Safety Alert Issued for Ozempic and GLP-1 Receptor Agonists by Watchdog

A safety warning regarding the potential risk of suicidal ideation and behaviors associated with GLP-1 receptor agonists, including Ozempic, has been issued by Australia's medicines regulator.

The Therapeutic Goods Administration (TGA) also cautioned that the possibility of Mounjaro (tirzepatide), another GLP-1 receptor agonist medication, diminishing the efficacy of oral contraceptives could not be dismissed.

Precision tracking for your journey

Join thousands using Shotlee to accurately track GLP-1 medications and side effects.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store

Get it onGoogle Play

According to the TGA's safety alert, updated product warnings have been issued for this class of prominent medications. These drugs are formally utilized in Australia for managing type 2 diabetes and obesity, and the update follows investigations conducted by international regulatory bodies.

Source Information

Originally published by WAtoday.Read the original article →

Keep exploring

More on Ozempic

Articles covering Ozempic dosing, side effects, and clinical updates.

Health & Wellness

Wegovy, Ozempic & Mounjaro: The Real Truth About Weight Loss Meds

A comprehensive guide to GLP-1 receptor agonists, understanding efficacy, managing side effects, and navigating the future of obesity treatment.

7 min read

Health & Wellness

Beyond Ozempic: The Future of Weight Loss & Metabolic Health Innovation

The GLP-1 revolution is just the beginning. This article delves into the cutting-edge advancements poised to reshape the future of weight loss and metabolic health, offering insights for patients and observers alike.

7 min read

Health & Wellness

Beyond Weight Loss: The Next Wave of GLP-1 Drugs

The revolutionary GLP-1 medications have transformed weight management, but the journey of innovation continues. Discover how upcoming drugs aim to enhance patient experience and outcomes.

7 min read

Same topic: Drug Safety

All Drug Safety articles →

Health & Wellness

Wegovy and Eye Stroke Risk: What You Need to Know

A recent study has raised questions about a rare but serious eye condition linked to Wegovy. Learn more about ischemic optic neuropathy (ION) and what this research means for patients using GLP-1 medications.

7 min read

Weight Loss & Metabolic Health

Retatrutide Trials: Why Extreme Weight Loss Isn't Always Safe

Clinical trials for the triple-agonist Retatrutide show promising weight loss, but 11% of high-dose participants dropped out due to side effects.

7 min read

Health

FDA requests removal of suicide warning labels from GLP-1 weight-loss medications

The Food and Drug Administration announced on Tuesday its desire to remove suicide warning labels from GLP-1 weight-loss medications. A comprehensive review of 91 trials revealed no heightened risk of suicidal thoughts or behaviors among users compared to placebo groups. This change aligns the labels with those of diabetes equivalents from the same manufacturers.

2 min read

More in Health

Health & Wellness

Ozempic & Beyond: Are GLP-1s Shifting America's Obesity Battle?

Once a distant rumor, the idea of widespread obesity in America is now being challenged by a new wave of medications. Discover how GLP-1 drugs are changing the landscape of weight management and what it means for public health.

8 min read

Health & Wellness

Beyond Ozempic: A New Pill Targets Fat Metabolism Without Appetite Loss

A groundbreaking pill developed by researchers at Karolinska Institutet and Stockholm University offers a new avenue for treating type 2 diabetes and obesity. Unlike injectable GLP-1 agonists, this oral medication targets muscle metabolism to enhance fat burning and improve blood sugar control, aiming to circumvent common side effects.

7 min read

Health & Wellness

Pfizer's Berobenatide: A New Monthly GLP-1 for Weight Loss?

Pfizer's investigational GLP-1 receptor agonist, berobenatide, has shown promising results in Phase 2b trials for weight loss. This article delves into the data, its implications for obesity treatment, and what it means for Pfizer's investment outlook.

7 min read